Shares of bluebird bio could hit their lowest value in more than six years following the Cambridge-based company's suspension of two trials of its gene therapy for sickle-cell anemia due to fears of serious side effects. The company said it’s investigating whether its drug had anything to do with the cancer discovered in two former patients.